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Abstract
Increased utrophin expression is known to reduce pathology in dystrophin-deficient skeletal muscles. Transgenic over-
expression of PGC-1a has been shown to increase levels of utrophin mRNA and improve the histology of mdx muscles.
Other reports have shown that PGC-1a signaling can lead to increased oxidative capacity and a fast to slow fiber type shift.
Given that it has been shown that slow fibers produce and maintain more utrophin than fast skeletal muscle fibers, we
hypothesized that over-expression of PGC-1a in post-natal mdx mice would increase utrophin levels via a fiber type shift,
resulting in more slow, oxidative fibers that are also more resistant to contraction-induced damage. To test this hypothesis,
neonatal mdx mice were injected with recombinant adeno-associated virus (AAV) driving expression of PGC-1a. PGC-1a
over-expression resulted in increased utrophin and type I myosin heavy chain expression as well as elevated mitochondrial
protein expression. Muscles were shown to be more resistant to contraction-induced damage and more fatigue resistant.
Sirt-1 was increased while p38 activation and NRF-1 were reduced in PGC-1a over-expressing muscle when compared to
control. We also evaluated if the use a pharmacological PGC-1a pathway activator, resveratrol, could drive the same
physiological changes. Resveratrol administration (100 mg/kg/day) resulted in improved fatigue resistance, but did not
achieve significant increases in utrophin expression. These data suggest that the PGC-1a pathway is a potential target for
therapeutic intervention in dystrophic skeletal muscle.
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Introduction
Dystrophin is a structural protein linking cytoskeletal actin to
the sarcolemma through the dystrophin-glycoprotein complex.
Duchenne muscular dystrophy (DMD) is an X-linked, progressive
muscle wasting disease caused by a non-functional dystrophin
protein [1]. Clinically, this disease is normally diagnosed in the
pre-school years as early developmental milestones are missed. It
then progresses rapidly to wheelchair confinement by the early
teen years followed by death due to respiratory or cardiac failure
by the third decade. Whole muscles become progressively more
fibrotic as greater numbers of fibers are lost to necrosis, impairing
muscle function.
The primary functional defect resulting from dystrophin
deficiency appears to be an increased susceptibility to contrac-
tion-induced rupture of the sarcolemma [2]. These sarcolemmal
lesions, and possibly leaky Ca
2+ channels [3,4], increase Ca
2+
influx into dystrophic fibers leading to protease activation [5,6,7]
and free radical formation via cytosolic [8,9,10] and mitochondrial
sources [11,12,13]. Excess Ca
2+ is sequestered first in the
sarcoplasmic reticulum (SR) followed by the mitochondria,
potentially contributing to pathologies in both organelles. Indeed,
increased Ca
2+ content in the SR and mitochondria has been
detected in dystrophic skeletal muscle [14,15]. Moreover,
impaired ATP production and metabolic abnormalities have also
been reported [16,17].
Upregulation of the dystrophin-related protein, utrophin, is
among the most promising of potential strategies for the treatment
of DMD [18]. Utrophin is a structural protein that shares many
similarities with dystrophin including actin and glycoprotein
binding domains as well as hinge regions and spectrin-like repeats.
Utrophin over-expression has been shown to rescue dystrophic
skeletal muscles from dystrophin-deficient mouse [19,20,21] and
dog models [22]. In mature skeletal muscle fibers utrophin
expression is primarily limited to the nuclei at neuromuscular
junctions, however, it is more widely expressed during regener-
ation [23]. Utrophin expression is under transcriptional [24], as
well as post-transcriptional control [25], and levels of utrophin A
gene expression are 3–4 fold higher in slow fiber types than in fast
fibers due to both transcriptional and post-transcriptional
modulation [26].
Given the apparent importance of utrophin upregulation as a
therapy for DMD it is critical to establish a strategy leading to
increased utrophin expression. Utrophin gene expression may be
induced by a complex that associates peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1a) and
GABP via Host Cell Factor (HCF) or neuregulin, acting on the N-
box domain of the utrophin gene [27,28,29].
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mitochondrial dysfunction experienced in dystrophic skeletal
muscle is also a high priority. Through a PGC-1a/ERRa/NRF-
1/MTFa pathway, PGC-1a can also drive oxidative gene
expression, potentially aiding damaged mitochondria and sup-
porting ATP production [28,30,31,32,33]. Regulation of these
divergent PGC-1a pathways appears to be phosphorylation
dependent where unphosphorylated PGC-1a may favor induction
of oxidative genes and MAPK p38 phosphorylation of PGC-1a
and/or GABP drives fate toward slow gene expression [27]. It was
previously shown that dystrophin-deficient mice with transgenic
PGC-1a over-expression had reduced muscle injury in both
sedentary and exercised conditions [27]. Many of these effects can
be attributed to increased utrophin expression and increased
oxidative capacity [27]. Despite this early success, it must be
recognized that there may be significant therapeutic benefits
during pre-natal development that would not be translatable to
human populations [34,35]. Consequently, there is a need to
determine the extent to which PGC-1a over-expression following
birth will attenuate the dystrophic phenotype.
Further, PGC-1a is activated by a number of upstream
pathways including activation of Sirt-1 and AMPK. Sirt-1
activation increases PGC-1a activity through deacetylation and
may be activated through resveratrol exposure [36,37,38].
Therefore resveratrol, or more potent Sirt-1 activators [39], may
provide a pharmacological means to increase PGC-1a signaling in
both mdx mice and eventually in DMD patients. Accordingly, we
also examined the potential of resveratrol to mimic the effects of
PGC-1a over-expression.
Results
PGC-1a expression was found to be on average 12-fold higher
in treated limbs when compared to control, with a range of 9.6–
14.5 fold increase (Figure 1). Over-expression was due to
exogenous PGC-1a produced by our vector, as confirmed using
PCR primers against the 39 UTR from our viral construct.
Muscle function (4 and 6 week old animals)
On the whole, muscle masses were reduced in the limbs over-
expressing PGC-1a compared to control injected limbs at both
four and six weeks (Table 1). At four weeks of age the TA, EDL,
and gastrocnemius were reduced approximately 10%, 10%, 26%,
respectively (p,0.05), and the soleus was similar between groups.
At six weeks the masses of the TA, EDL, gastrocnemius, and soleus
were reduced by approximately 20%, 15%, 27%, and 12%,
respectively (p,0.05).
The EDL and soleus were further examined for muscle
function. Due to the reduction in muscle mass, there was a
corresponding reduction in muscle CSA in both the soleus and
EDL at four and six weeks (Table 2). Despite the reductions in
muscle mass and CSA, tetanic force was similar for both muscles
at four weeks and at six weeks. Thus, despite their smaller size,
muscles over-expressing PGC-1a were able to maintain force
comparable, if not greater than control muscles. Finally, PGC-1a
over-expression caused a 12% increase in specific tension in the six
week EDL.
To determine the extent to which PGC-1a improved resistance
to contraction induced injury, muscles underwent a series of five
lengthening contractions. Forces were scaled to the maximal force
generated during the first contraction. PGC-1a over-expression
allowed a maintenance of 30–40% (p,0.05) greater force output
during each contraction in the EDL (Figure 2). PGC-1a over-
expression failed to improve resistance to contraction induced
injury in the soleus (Figure S1). In order to determine the extent to
which increasing PGC-1a would improve fatigue resistance, an
Figure 1. Virally-mediated gene transfer. Six weeks following PGC-
1a gene delivery total (PGC-1a) and viral (V-PGC-1a) expression was
increased in treated limbs compared to untreated limbs (n=6/group).
* indicates p,0.05.
doi:10.1371/journal.pone.0030063.g001
Table 1. PGC-1a induced changes in muscle mass.
EDL (mg) Soleus (mg) Gastroc (mg) TA (mg)
4 Week mdx 5.360.3 3.760.1 62.063 22.462
4 Week mdx-PGC-1a 4.860.5* 3.660.2 45.864* 20.062*
6 Week mdx 9.960.5 8.860.6 131.966 51.362
6 Week mdx-PGC-1a 8.460.5* 7.860.6* 96.466* 41.662*
Following four (n=7) or six (n=13) weeks of PGC-1a over-expression in mdx
mice muscle mass was generally reduced.
*indicates significantly different from corresponding control. EDL – extensor
digitorum longus, Gastroc – gastrocnemius, TA – tibialis anterior.
doi:10.1371/journal.pone.0030063.t001
Table 2. PGC-1a induced changes in muscle function.
CSA (mm
2)
Tetanic Force
(mN)
Specific Tension
(N/cm
2)
4 wk mdx sol 0.6260.03 55.465 9.160.8
4 wk mdx-PGC-1a sol 0.5760.04* 61.7661 0 . 7 61.2
4 wk mdx EDL 1.160.05 156691 4 60.6
4 wk mdx-PGC-1a EDL 1.060.08* 155613 15.560.8
6 wk mdx sol 0.9760.05 142661 4 . 6 60.5
6 wk mdx-PGC-1a sol 0.8760.05* 119611 13.761.0
6 wk mdx EDL 1.760.06 292623 16.861.0
6 wk mdx-PGC-1a EDL 1.560.06* 289615 19.161.0*
Following four (n=7) or six (sol n=6; EDL n=13) weeks of PGC-1a over-
expression muscle function in the soleus and EDL was altered.
*indicates significantly different from corresponding control. Wk – week, sol –
soleus, EDL – extensor digitorum longus, CSA – cross sectional area.
doi:10.1371/journal.pone.0030063.t002
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maximally stimulated every second for ten minutes. The relative
force generated during the final contraction was approximately
65% greater in the soleus (p,0.05) and 34% greater in the EDL
(p,0.05) from six week old muscles over-expressing PGC-1a
compared to control limbs (Figure 3). This pattern was also
observed in the soleus taken from four week old animals (Figure
S2). Importantly, muscle mass was not well correlated with fatigue
resistance indicating changes observed are the result of improved
physiology, not better oxygen diffusion in smaller muscles (Figure
S3). Finally, PGC-1a over-expression reduced damage and
centralized nucleation (indicator of ongoing degeneration/regen-
eration) in soleus muscles (Figure 4). Fiber area distribution was
similar between groups (Figure S4).
Protein expression (6 week old animals)
As the overall condition and function of muscles over-expressing
PGC-1a was improved, we sought to determine the extent to
which PGC-1a over-expression induced expression of utrophin
and other proteins related to slow muscle. In order to maximize
data produced from these animals, Western blots were performed
in gastrocnemius with limited confirmation in the soleus. Western
blot analysis revealed that utrophin expression was increased two
fold in the gastrocnemius (p,0.05; Figure 5) and approximately
17% in the soleus (Figure S5; p,0.05) in response to PGC-1a
over-expression. To confirm that the increase in utrophin was due
to an absolute increase in protein, the membrane protein spectrin
and the regulatory protein troponin were evaluated. In both cases,
they were similar between groups indicating that the increase in
utrophin is due to protein accumulation rather than merely a
reflection of smaller fibers with increased surface area to volume
ratios.
Slow myosin heavy chain was increased by three fold in PGC-
1a over-expressing muscle compared to control (Figure 5). We
confirmed these data by quantifying the fiber type switch
occurring in the soleus through histological determination of type
I and type II fibers (Figure 6). Consistent with the Western blot
analysis, an increase in the total number and relative number of
type I staining fibers was detected as well as a corresponding
decrease in type II fibers.
PGC-1a has also been implicated in mitochondrial biogenesis.
As it was apparent that muscles were more fatigue resistant we
assessed several oxidative and mitochondrial markers. Cyto-
chrome C, complex IV subunit IV, myoglobin, and UCP-1 were
increased between 40% and 2.5 fold (p,0.05) in PGC-1a over-
expressing muscles while Hsp 60 remained unchanged when
compared to control limbs (Figure 5).
Finally, we made initial determinations of several PGC-1a
pathway activity regulators. Upstream activator Sirt-1 was
increased 2.25 fold, however, an alternative activator, phospho-
p38, was reduced by 33% in treated limbs when compared to
control limbs with p38 similar between groups (Figure 5). Finally,
NRF-1 was decreased by 50% in PGC-1a over-expressing muscle
when compared to control muscle.
6 mo animals
Six months following injection of a virus causing expression of
PGC-1a into the subxyphoid region, diaphragm function was
assessed. As diaphragm strips may vary by size, we report only
specific tension. Specific tension was similar between treated and
untreated animals (Figure S6). PGC-1a over-expression improved
resistance to contraction induced injury by 20–40% in contrac-
tions 3–5 (p,0.05; con 4 – p=0.08; Figure 7), however fatigue
resistance was similar between groups (Figure 7). Fibrosis was also
Figure 2. Relative force reduction in 6 wk old EDL’s following
lengthening contractions. PGC-1a over-expressing limbs were
better able to maintain force during lengthening contractions when
compared to control limbs (n=13/group). Data from age matched C57
animals is included for reference purposes. * indicates p,0.05. Con –
contraction.
doi:10.1371/journal.pone.0030063.g002
Figure 3. PGC-1a protects against muscle fatigue. Muscle fatigue
curves in the soleus (n=6/group) and EDL (n=7/group) (A) during
10 minutes of a fatigue protocol where muscles are contracted every
second for 10 minutes. Force of the final contraction (B) was
significantly higher in the soleus and EDL muscles over-expressing
PGC-1a when compared to control muscle. * indicates p,0.05.
doi:10.1371/journal.pone.0030063.g003
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non-significant trend toward type I fiber expression in muscle
over-expressing PGC-1a compared to control (data not shown).
Resveratrol
To determine if an orally available Sirt-1 activator could cause
similar benefits to dystrophic muscle, one month old mdx mice
were fed diets containing 0 mg/kg/day, 100 mg/kg/day or
400 mg/kg/day resveratrol. Eight weeks of 100 mg/kg/day
resveratrol feeding reduced body weights with a corresponding
reduction in muscle mass, in similar fashion to virally induced
PGC-1a (Table 3). Animals fed a diet containing 100 mg/kg/day
resveratrol demonstrated increased fatigue resistance in the soleus
(Figure 8), however failed to increase resistance to injury in the
soleus or EDL (Figure 9). Further, elevated oxidative or slow
proteins could not be detected, though utrophin expression tended
to be increased in resveratrol treated animals (p=0.13; data not
shown).
Due to the high mortality rate of the 400 mg/kg/day
resveratrol group limited data was collected. Body weight and
muscle mass of the soleus, gastrocnemius, TA, and EDL were
similar between groups. Of potential concern was that relative
heart weight was increased slightly in treated animals compared to
control (4.460.17 mg/g Con; 5.060.07 mg/g; p,0.05). Muscle
function in the EDL was similar between treated and control
animals. In the soleus tetanic force was 25% greater (p,0.05) in
treated animals compared to control (164640 mN Control;
21661.2 mN Resveratrol) and specific tension was increased
33% (p,0.05) in treated animals compared to control
(10.361.2 N/cm2 Control; 15.461.52 N/cm2).
Discussion
Pharmacological agents to treat Duchenne muscular dystrophy
have advanced little since the late 1970s when steroid use
appeared [40]. More recently an array of strategies has been
proposed targeting various components of the disease
[6,7,18,41,42,43,44]. Utrophin over-expression has repeatedly
been used in animal models as an effective means of rescuing
dystrophic skeletal muscle, though a practical method of human
implementation has not yet been developed [18]. While it has
been shown that transgenic PGC-1a over-expression would
increase utrophin expression in dystrophic skeletal muscles of the
mdx mouse [27], this has not been shown in the case of postnatal
upregulation, which is of potential therapeutic significance. In
addition, developmental abnormalities have been reported in
dystrophin deficient muscle [34,35] that could be potentially aided
by transgenic PGC-1a over-expression. Hence, it is critical to
establish that PGC-1a over-expression following uterine develop-
ment will reduce disease severity.
These data represent the first evidence that activation of the
PGC-1a pathway in post-natal dystrophic (mdx) mice will induce
expression of proteins associated with the slow gene program.
Consistent with what had been shown in dystrophic skeletal
muscle taken from transgenic animals over-expressing PGC-1a
[27], utrophin expression was elevated in treated limb muscles.
Further, the increase in utrophin expression occurred in muscle
with fewer centralized nuclei meaning increased utrophin
expression in treated limbs was over and above that seen resulting
from typical regeneration-mediated utrophin expression [23]. We
also established that type I MHC is over-expressed, indicating a
Figure 4. PGC-1a over-expression reduces disease-related muscle injury. 106micrographs of six week old soleus muscles following H and E
staining (A and B). (C) The total areas of necrotic, H&E negative, or regenerating cells were quantified and is expressed as a percent of the total soleus
area. In addition, laminin was detected with a fluorescently labeled antibody (not shown) in order to determine central nucleation. (D) PGC-1a caused
a reduction in central nucleation. N=5/group; * indicates p,0.05.
doi:10.1371/journal.pone.0030063.g004
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healthy and dystrophic muscle Type I fibers have greater utrophin
expression than type II fibers [26,45]. Further supporting a type I
shift was a reduction in muscle mass, though corresponding
reductions in muscle fiber cross sectional area were not detected
likely due to the high variability of fiber size in this study.
Muscle from limbs over-expressing PGC-1a was better able to
maintain force production during a fatigue protocol when
compared to control muscle reflecting an improved endurance
capacity. Accordingly, expression of the mitochondrial proteins
cytochrome C, UCP-1, and complex IV (subunit IV) as well as
myoglobin were increased in PGC-1a over-expressing limbs
compared to control limbs. Given the improved endurance
capacity and increased expression of oxidative proteins, it is likely
that the cells are more capable of ATP production and may also
indicate an increased mitochondrial number or volume. Specula-
tively, aside from an increased platform to produce ATP,
increased mitochondrial volume is likely beneficial to dystrophic
muscle as a secondary well for Ca
2+ sequestering [12,14]
potentially limiting the contributions of calpains [5,6,46] and free
radicals [8,9,10] to disease-related muscle injury. Further, as a
consequence of increased mitochondrial volume we would
hypothesize that there is less Ca
2+/mitochondrion leading to less
mitochondrial dysfunction throughout the cell providing an
additional means for increased ATP production. The metabolic
aspect of dystrophin-deficiency is an important consideration as it
appears very early in disease progression [47,48] and may
represent a primary mechanism of disease pathology.
In addition to measuring slow and oxidative protein expression
we also assessed PGC-1a pathway changes as a result of PGC-1a
over-expression. Interestingly, Sirt-1 expression was increased in
treated muscle when compared to control despite being upstream
of PGC-1a. Sirt-1 is a deacetylase that acts on PGC-1a to increase
its activity [36,37,38]. It seems likely that Sirt-1 activity could lead
to either oxidative or slow gene activation. In contrast,
phosphorylated p38 and NRF-1 content were reduced in PGC-
1a over-expressing muscle. Long-term reduction in NRF-1
expression may help to explain the observation that resistance to
fatigue is similar in treated and control 6 mo old diaphragms. It is
possible that this observation is an attempt to decrease signaling
through the PGC-1a pathway in the face of massive PGC-1a over-
expression and that NRF-1 and phosphorylation of PGC-1a by
p38 represent points of regulation. Alternatively, reduced
phospho-p38 expression may also indicate that cells from treated
limbs are under less stress than cells from control limbs [49,50].
For the potential benefits of PGC-1a to be evaluated in human
DMD patients, a pharmacological approach must be identified.
Previous studies using resveratrol to activate Sirt-1 (a PGC-1a
activator) demonstrated increased oxidative gene expression
[36,51]. Activation of this pathway has protected mice against
diabetes related pathologies as well as helped to prevent obesity
[36,51]. Thus, in an independent experiment, mdx mice were fed
100 mg/kg resveratrol or control diet for two months. Supple-
mentation of the diet with resveratrol resulted in improved fatigue
resistance and reduced muscle weights, which is consistent with
observations made in comparing PGC-1a over-expressing limbs to
control limbs. It did not, however, improve resistance to
contraction-induced injury though tended to increase utrophin
content. Thus, resveratrol mimicked some, but not all, changes
associated PGC-1a pathway activation suggesting that either an
alternative dose of resveratrol or more potent Sirt-1 activator [39]
should be evaluated.
An alternative approach is to provide orally available PPAR
agonists. Indeed, a PPAR agonist was recently used to increase
utrophin expression and reduce eccentric muscle injury in mdx
mice [52]. Caution should be taken with use of these drugs,
however, as PPAR agonists known as thiazolidinediones have
recently been linked to heart disease [53,54,55] and cancer [56].
Related, our initial study design called for an mdx group to be
supplemented with 400 mg/kg/day, however, despite early
replacement of lost animals, only three animals reached the end
of the eight week dosing regimen indicating potential toxicity with
this drug. Given though the success of other investigations at this
dose it may point to a source dependent effect rather than an effect
of the resveratrol dose, per se.
In summary, activation of the PGC-1a pathway could lead to
dystrophic muscles that are more resistant to contraction induced
damage and fatigue. Further, we demonstrated that the basis of
improved muscle function likely involves a shift to slower fiber
types with concomitant increases in utrophin expression. In the
dystrophic skeletal muscles of humans with DMD, type II fibers
have been shown to undergo degeneration before slow fiber types,
providing evidence in humans of the protective effects of the slow
gene program, and likely increased utrophin levels [57].
Moreover, it has been shown that variability in disease severity
in DMD boys is linked to differences in utrophin expression levels
Figure 5. Protein expression following 6 weeks of PGC-1a over-
expression. Slow genes are shown in black (utrophin – A, slow myosin
heavy chain – B) oxidative genes are shown in gray (cytochrome C – C,
uncoupling protein-1 – D, complex IV subunit IV – E, myoglobin – F, Hsp
60 – G), pathway genes are shown in white (Sirt-1 – H, nuclear
respiratory factor -1 – I, p38 – J, phospho-p38 – K), and controls have
diagonal lines (Actin – L, Troponin – M, Spectrin – N). Relative change
compared to control limbs (n=6/group) (O). * indicates p,0.05
compared to control limbs.
doi:10.1371/journal.pone.0030063.g005
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the percentage of slow vs. fast fibers among individual DMD
patients. If so, then the approach of shifting human DMD muscles
toward an increased slow-twitch fiber profile may indeed provide
therapeutic benefit. However, the degree of benefit seen in the
mdx mouse is likely to be much greater since it begins with higher
fast fiber type content than humans. Future studies will attempt to
ascertain how much benefit is tied to the possible fiber type shift
and the impact on both slow and fast-twitch muscles needs to be
differentially evaluated.
Methods
Animal treatments
All animals procedures were done in accordance with the
guiding principles of animal use established by the American
Physiological Society and were approved the IACUC at the
University of Pennsylvania (protocol number 801770). In order to
test our hypotheses, neonatal mdx mice from our colony were
injected with adeno-associated virus (AAV) pseudotype 2/6
expressing mouse PGC-1a. To inject pups, a technique called
cryosedation was used. Briefly, pups were placed on ice with a thin
plastic barrier until they could be handled without excessive
movement, allowing accurate and precise injection [59]. In one
investigation, mice were injected with 1610
11 gc delivered in
50 ul to the lower right hind limb with a depth of approximately
1 mm while contralateral limbs were injected with an equal
volume of saline [44,60,61]. This technique is effective for
achieving transgene expression in the soleus, gastrocnemius,
tibialis anterior, and extensor digitorum longus. Mice were
sacrificed at four and six weeks of age. For long-term studies,
neonatal mice were injected with virus as above in the subxyphoid
region in order to infect the diaphragm or given a sham injection
and sacrificed at six months of age [44,62].
Figure 6. Myosin fiber type distribution in treated and control soleus muscles. Histological sections of soleus (106) were exposed to an
antibody against the slow isoform of myosin heavy chain (A). A C57 (healthy) section is included as reference (Left). The control limb (middle) shows
moderate type I content. The corresponding injected limb (Right) clearly has an elevation in type I content. In serial sections, we also evaluated typeI I
myosin heavy chain content (B). A C57 (healthy) section is included for reference (Left). The control limb (middle) shows high levels of type II
expression. PGC-1a caused a reduced expression of type II fibers (Right). The absolute fiber numbers from each section expressing type I and II fibers
were counted and recorded (C). PGC-1a caused a shift toward type I fibers and away from type II fibers. These were then made relative to total fiber
number (D). Once again, a type I shift is observed. N=9/group; * indicates p,0.05.
doi:10.1371/journal.pone.0030063.g006
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which an orally available Sirt-1 activator could mimic the effects
of virally mediated PGC-1a over-expression, one month old male
mdx mice were fed either a control diet (AIN-93; Bioserv) or a
diet containing 100 mg/kg/day of resveratrol (Sigma) for eight
weeks. We also included a group of animals that was given
400 mg/kg/day resveratrol. Only 3 treated animals in this group
survived the eight week study period, despite early efforts to
replace several lost animals, hence only limited data was
collected.
To prepare virus, PGC-1a cDNA was amplified from mouse
skeletal muscle mRNA using primers that added restriction sites at
the 59 and 39 ends. The restriction sites allowed the PGC-1a
transgene to be inserted into an expression vector developed at the
Vector Core at the University of Pennsylvania designed to express
PGC-1a under control of the constitutive chicken beta actin
promoter with CMV enhancer. After confirming the sequence of
the insert and inverted terminal repeats (ITR) in the plasmid it was
amplified for viral preparation. Vectors were produced according
to the previously described pseudotyping protocol by the Vector
Core at the Children’s Hospital of Philadelphia [63]. Briefly,
recombinant AAV genomes containing AAV2 ITR’s were
packaged by triple transfection of 293 cells with a cis-plasmid
containing the PGC-1a transgene, an adenovirus helper plasmid,
and a chimeric trans-plasmid containing the AAV2 rep gene fused
to the capsid gene of the AAV6 serotype. AAV6 has been
previously shown to successfully deliver transgenes into skeletal
muscle [64].
Figure 7. PGC-1a partially maintains diaphragmatic function
six months following gene transfer. Neonatal mdx mice were
injected in the sub-xyphiod region in order to cause diaphragmatic
infection and sacrificed 6 mo later. Diaphragms over-expressing PGC-1a
were more resistant to contraction induced injury (n=4 Con; n=7 PGC-
1a) (A; Contraction 4 – p=0.08), however, fatigue resistance was similar
between groups (n=7/group) (B). * indicates p,0.05.
doi:10.1371/journal.pone.0030063.g007
Table 3. Muscle and body mass following eight weeks of
100 mg/kg resveratrol feeding.
mdx mdx-Resveratrol
Body mass (g) 3361.3 2761*
EDL (mg) 16.160.8 11.561.2*
Rel EDL (mg/g) 0.4960.02 0.4260.01*
Soleus (mg) 11.560.7 9.560.3*
Rel Soleus (mg/g) 0.2560.01 0.3560.01
TA (mg) 79656 5 62*
Rel TA (mg/g) 2.460.1 2.460.05
Gastroc (mg) 191611 14964*
Rel Gastroc (mg/g) 5.860.15 5.560.11
*indicates significantly different from control. N=8/group. EDL - extensor
digitorum longus, Rel – relative, TA – tibialis anterior, Gastroc – gastrocnemius.
doi:10.1371/journal.pone.0030063.t003
Figure 8. Resveratrol supplementation increased fatigue
resistance in dystrophic skeletal muscle. One month old mdx
mice were fed a diet containing 100 mg/kg/day resveratrol or control
diet for eight weeks. Resveratrol feeding increased fatigue resistance in
the soleus (A) and force generated during the final contraction (B ) was
higher in treated animals when compared to control. n=8 Con; n=6
Res; * indicates p,0.05.
doi:10.1371/journal.pone.0030063.g008
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Upon animal sacrifice, muscle mechanics testing was performed
on muscles removed from the mice at the Physiological Assessment
Core of the Wellstone Muscular Dystrophy Cooperative Center at
the University of Pennsylvania. All animals were given an injection
of a ketamine/xylazine cocktail to induce a surgical level of
anesthesia. Limb muscles or diaphragms were removed as
appropriate, weighed, and contractile function was performed
according to standard techniques [6,44,62,65,66]. Briefly, function
was determined with an Aurora dual mode lever system (Ontario,
Canada) interfaced with a Dell Dimension 2400 desk top
computer and controlled with DMC software (version 3.2).
Muscles were placed in oxygenated Ringers solution such that
the proximal and distal tendons were attached to clamps. One end
was connected to a force transducer and the other to an anchor.
Bilateral electrodes were placed longitudinally adjacent to the
muscle to create a field upon stimulation. Optimum length (Lo)
was determined using standard techniques followed by supramax-
imal stimulation (EDL – 120 Hz, Sol – 100 Hz, diaphragm –
100 Hz) in order to achieve tetanic contractions. Each muscle
performed three 500 msec tetanic contractions at Lo with five
minutes between each trial. Cross sectional area (CSA) and specific
tension were estimated using standard equations and constants
[67]. Some EDL muscles, solei, and one diaphragm strip were
given a series of five lengthening contractions in order to
determine resistance to damage (80 Hz for 500 msec followed
by 200 msec at 110% Lo). Other EDL muscles, solei and one
diaphragm strip were stimulated for once per second for
10 minutes (200 msec pulse, 100 Hz, 330 msec duration) in order
to determine resistance to fatigue.
Histology
Muscles were removed, weighed, and frozen in melting
isopentane. Ten micrometer histological sections were cut at
230uC with a Leica CM3000 cryostat (Bannockburn, IL).
Hematoxylin and eosin staining were accomplished according to
standard techniques. Immunohistochemistry was performed as
follows: tissues were washed in PBS for 10 minutes and blocked by
covering each section with 5% BSA for 15 minutes. Sections were
then incubated overnight at 4uC in primary antibody (MHCs,
Nova Castra, New Castle, UK; Laminin, Neomarkers, Fremont,
CA) at a dilution of 1:100 in 5% BSA. They were then washed
three times in PBS and incubated with secondary antibody at a
dilution of 1:200 in 5% BSA for one hour in the dark. Sections
were washed three times for ten minutes in PBS and the coverslip
mounted with Vectashield with DAPI. In order to determine the
extent to which central nucleation was altered by our intervention
the total number of cells in a cross section was determined
(approximately 1,000 cells). Next, muscle cells containing a
centralized nucleus were counted. Data is expressed as the percent
of total muscle cells counted with a centralized nucleus. To
measure the cross sectional area of muscle fibers the cross sectional
area of each muscle fiber in a section was measured using
calibrated Openlab software. The cross sectional area of each fiber
was recorded then assigned to a size range (binning). The mean
percentage of fibers within a bin was determined for each size
range for both untreated and treated limbs.
Biochemistry
Selected muscles were also removed, weighed and frozen in
liquid nitrogen for biochemical analysis. Western blotting was
done as previously described with minor modifications [68].
Muscle was powdered on dry ice and lysed using lysis buffer at a
1:10 dilution [6]. Protein concentration was determined by the
method of Biuret. Following dilution of whole homogenate to
2.5 mg/ml in reducing buffer, 25 mg protein was loaded into 4–
20% gradient gels and separated vertically by molecular weight.
Transfer was accomplished by using the I-blot system from
Invitrogen (Carlsbad, CA). Primary antibodies were used as
described below in 1% milk dissolved in 0.1% Tween-20 buffered
TBS overnight at 4uC. Primary antibodies were used as follows:
utrophin 1:100 (Vector – Burlingame, CA), cytochrome C 1:1000
(Santa Cruz, Santa Cruz, CA), TnI 1:1000 (Santa Cruz), Hsp 60
1:1000 (Abcam – Cambridge, MA), MHCs 1:1000 (Nova Castra),
Sirt-1 1:1000 (Millipore – Bedford, MA), phospho-p38 1:1000
(Cell Signaling Technology – Boston, MA), p38 1:1000 (Cell
Signaling Technology), UCP-1 1:100 (Abcam), Complex IV
subunit IV 1:2500 (Mitosciences – Eugene, OR), NRF-1 1:000
(Abcam), myoglobin 1:500 (Santa Cruz), actin 1:2000 (Neomar-
kers), and spectrin 1:1000 (Novacastra). Secondary antibodies
were incubated for one hour at room temperature at 26primary
dilution such that an antibody used at 1:1000 for primary antibody
would receive a 1:2000 dilution of secondary in 1% milk dissolved
in TTBS. Blots were exposed to SuperSignal (Thermo Scientific,
Rockford, IL) for 3–4 minutes and emitted light captured with
film. Following development, blots were quantified using Kodak
software (Rochester, NY) with the automated band find function,
where possible, in order to remove researcher bias. Further, beta-
actin was quantified and used as a loading control to assure equal
Figure 9. Resveratrol supplementation did not improve
resistance to contraction induced injury. Feeding a diet contain-
ing 100 mg/kg/day resveratrol for eight weeks did not improve
resistance to contraction induced injury in (A) the EDL (n=8 Con;
n=6 Res) or (B) the soleus (n=8/group) when compared to control.
doi:10.1371/journal.pone.0030063.g009
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differ between groups for any gel run indicating consistent loading.
RNA was isolated according to standard techniques. Briefly,
muscle was powdered over dry ice and homogenized with Trizol.
Following centrifugation and extraction with chloroform, RNA
was precipitated with isopropanol. The RNA pellet was resus-
pended in nuclease free water. rtPCR was performed to convert
RNA to cDNA, and then qPCR was used to assess gene
expression. Two sets of primers were designed to distinguish
between total and exogenous PGC-1a. The first, which measured
total PGC-1a, was designed internally within the gene. The
second set, which was used to determine viral expression of PGC-
1a, was directed against the viral 39 UTR.
Statistics
Data collected as part of PGC-1a gene transfer studies, where
control and treated limbs are found within the same animal, were
compared using a paired T-test. Data collected as part of
resveratrol supplementation studies were compared using a T-
test. Resistance to fatigue was determined by comparing force
generated during the final contraction. Significance was deter-
mined a priori at p,0.05. Data are presented as means 6 SEM
unless otherwise noted.
Supporting Information
Figure S1 PGC-1a over-expression fails to improve
resistance to contraction induced injury in the soleus.
Six weeks following viral injection of a virus driving PGC-1a,
treated solei had a similar resistance to contraction induced injury
as control muscle. n=7/group.
(PDF)
Figure S2 Resistance to fatigue is improved with PGC-
1a gene transfer. Four weeks following injection of virus driving
PGC-1a, soleus muscles were more resistant to fatigue than
control. The fatigue curve (A) was significantly different from
control and the force generated during the final contraction (B)
was higher in PGC-1a over-expressing muscle when compared to
control. N=7/group; * indicates p,0.05.
(PDF)
Figure S3 Muscle mass and fatigue resistance were
poorly correlated. The percent of initial force from fatigue
curves was plotted against muscle mass in order to determine the
extent to which muscle size may impact fatigue data. As four and
six week old mdx hind limb muscle are physiologically distinct and
treated and control limbs are physiologically distinct they were
fitted independently. R
2 and corresponding p-values were as
follows: 4 wk mdx – 0.006, p,0.86; 4 wk mdx-PGC-1a – 0.055,
p,0.61; 6 wk mdx – 0.07, p,0.61; 6 wk mdx-PGC-1a – 0.42,
p,0.15.
(PDF)
Figure S4 Fiber area distribution in the soleus 6 wks
following gene transfer. The percent of fibers within a given
cross sectional area range was determined for treated and
untreated soleus muscles (approximately 1,000 fibers/muscle).
Fiber area distribution was similar between groups. n=5/group.
(PDF)
Figure S5 Protein expression in the soleus 6 wks
following gene transfer. Representative Western blots from
the soleus (A) were quantified and generally support the notion of
increased utrophin (B) and expression of oxidative proteins (C and
D). n=9/group; * indicates P,0.05.
(PDF)
Figure S6 Specific tension in the diaphragm six months
following gene transfer. Six months of PGC-1a over-
expression (n=7) did not improve the specific tension in
diaphragm strips compared to control muscle (n=8).
(PDF)
Figure S7 Fiber and Fibrotic area in the diaphragm. Six
months following PGC-1a over-expression, fibrotic area and fiber
area were similar between treated and untreated animals (n=6/
group).
(PDF)
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